---
document_datetime: 2025-11-23 07:49:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/qutavina.html
document_name: qutavina.html
version: success
processing_time: 0.0988206
conversion_datetime: 2025-12-23 21:34:22.806843
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Qutavina

[RSS](/en/individual-human-medicine.xml/67329)

##### Withdrawn

This medicine's authorisation has been withdrawn

teriparatide

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Qutavina](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 24 November 2020, the European Commission withdrew the marketing authorisation for Qutavina (teriparatide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, EuroGenerics Holdings B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Qutavina was granted marketing authorisation in the EU on 27 August 2020 for the treatment of osteoporosis. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU since 2020. Qutavina was a duplicate application to Livogiva, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Livogiva.

The European Public Assessment Report (EPAR) for Qutavina is updated to indicate that the marketing authorisation is no longer valid.

Qutavina : EPAR - Medicine overview

Reference Number: EMA/349913/2020

English (EN) (726.88 KB - PDF)

**First published:** 18/01/2021

[View](/en/documents/overview/qutavina-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-970)

български (BG) (1.35 MB - PDF)

**First published:**

18/01/2021

[View](/bg/documents/overview/qutavina-epar-medicine-overview_bg.pdf)

español (ES) (725.86 KB - PDF)

**First published:**

18/01/2021

[View](/es/documents/overview/qutavina-epar-medicine-overview_es.pdf)

čeština (CS) (798.67 KB - PDF)

**First published:**

18/01/2021

[View](/cs/documents/overview/qutavina-epar-medicine-overview_cs.pdf)

dansk (DA) (724.75 KB - PDF)

**First published:**

18/01/2021

[View](/da/documents/overview/qutavina-epar-medicine-overview_da.pdf)

Deutsch (DE) (730.66 KB - PDF)

**First published:**

18/01/2021

[View](/de/documents/overview/qutavina-epar-medicine-overview_de.pdf)

eesti keel (ET) (709.32 KB - PDF)

**First published:**

18/01/2021

[View](/et/documents/overview/qutavina-epar-medicine-overview_et.pdf)

ελληνικά (EL) (819.31 KB - PDF)

**First published:**

18/01/2021

[View](/el/documents/overview/qutavina-epar-medicine-overview_el.pdf)

français (FR) (728.34 KB - PDF)

**First published:**

18/01/2021

[View](/fr/documents/overview/qutavina-epar-medicine-overview_fr.pdf)

hrvatski (HR) (747.09 KB - PDF)

**First published:**

18/01/2021

[View](/hr/documents/overview/qutavina-epar-medicine-overview_hr.pdf)

italiano (IT) (724.03 KB - PDF)

**First published:**

18/01/2021

[View](/it/documents/overview/qutavina-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (815.37 KB - PDF)

**First published:**

18/01/2021

[View](/lv/documents/overview/qutavina-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (749.58 KB - PDF)

**First published:**

18/01/2021

[View](/lt/documents/overview/qutavina-epar-medicine-overview_lt.pdf)

magyar (HU) (793.63 KB - PDF)

**First published:**

18/01/2021

[View](/hu/documents/overview/qutavina-epar-medicine-overview_hu.pdf)

Malti (MT) (798.96 KB - PDF)

**First published:**

18/01/2021

[View](/mt/documents/overview/qutavina-epar-medicine-overview_mt.pdf)

Nederlands (NL) (698.91 KB - PDF)

**First published:**

18/01/2021

[View](/nl/documents/overview/qutavina-epar-medicine-overview_nl.pdf)

polski (PL) (797.33 KB - PDF)

**First published:**

18/01/2021

[View](/pl/documents/overview/qutavina-epar-medicine-overview_pl.pdf)

português (PT) (725.9 KB - PDF)

**First published:**

18/01/2021

[View](/pt/documents/overview/qutavina-epar-medicine-overview_pt.pdf)

română (RO) (746.69 KB - PDF)

**First published:**

18/01/2021

[View](/ro/documents/overview/qutavina-epar-medicine-overview_ro.pdf)

slovenčina (SK) (796.21 KB - PDF)

**First published:**

18/01/2021

[View](/sk/documents/overview/qutavina-epar-medicine-overview_sk.pdf)

slovenščina (SL) (792.9 KB - PDF)

**First published:**

18/01/2021

[View](/sl/documents/overview/qutavina-epar-medicine-overview_sl.pdf)

Suomi (FI) (722.29 KB - PDF)

**First published:**

18/01/2021

[View](/fi/documents/overview/qutavina-epar-medicine-overview_fi.pdf)

svenska (SV) (724.89 KB - PDF)

**First published:**

18/01/2021

[View](/sv/documents/overview/qutavina-epar-medicine-overview_sv.pdf)

Qutavina : EPAR - Risk-management-plan summary

English (EN) (650.67 KB - PDF)

**First published:** 18/01/2021

[View](/en/documents/rmp-summary/qutavina-epar-risk-management-plan-summary_en.pdf)

## Product information

Qutavina : EPAR - Product Information

English (EN) (2.2 MB - PDF)

**First published:** 18/01/2021

[View](/en/documents/product-information/qutavina-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-751)

български (BG) (2.99 MB - PDF)

**First published:**

18/01/2021

[View](/bg/documents/product-information/qutavina-epar-product-information_bg.pdf)

español (ES) (2.54 MB - PDF)

**First published:**

18/01/2021

[View](/es/documents/product-information/qutavina-epar-product-information_es.pdf)

čeština (CS) (3.18 MB - PDF)

**First published:**

18/01/2021

[View](/cs/documents/product-information/qutavina-epar-product-information_cs.pdf)

dansk (DA) (2.6 MB - PDF)

**First published:**

18/01/2021

[View](/da/documents/product-information/qutavina-epar-product-information_da.pdf)

Deutsch (DE) (2.65 MB - PDF)

**First published:**

18/01/2021

[View](/de/documents/product-information/qutavina-epar-product-information_de.pdf)

eesti keel (ET) (2.6 MB - PDF)

**First published:**

18/01/2021

[View](/et/documents/product-information/qutavina-epar-product-information_et.pdf)

ελληνικά (EL) (3.89 MB - PDF)

**First published:**

18/01/2021

[View](/el/documents/product-information/qutavina-epar-product-information_el.pdf)

français (FR) (2.58 MB - PDF)

**First published:**

18/01/2021

[View](/fr/documents/product-information/qutavina-epar-product-information_fr.pdf)

hrvatski (HR) (2.64 MB - PDF)

**First published:**

18/01/2021

[View](/hr/documents/product-information/qutavina-epar-product-information_hr.pdf)

íslenska (IS) (2.55 MB - PDF)

**First published:**

18/01/2021

[View](/is/documents/product-information/qutavina-epar-product-information_is.pdf)

italiano (IT) (2.63 MB - PDF)

**First published:**

18/01/2021

[View](/it/documents/product-information/qutavina-epar-product-information_it.pdf)

latviešu valoda (LV) (3.16 MB - PDF)

**First published:**

18/01/2021

[View](/lv/documents/product-information/qutavina-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.73 MB - PDF)

**First published:**

18/01/2021

[View](/lt/documents/product-information/qutavina-epar-product-information_lt.pdf)

magyar (HU) (3.14 MB - PDF)

**First published:**

18/01/2021

[View](/hu/documents/product-information/qutavina-epar-product-information_hu.pdf)

Malti (MT) (3.27 MB - PDF)

**First published:**

18/01/2021

[View](/mt/documents/product-information/qutavina-epar-product-information_mt.pdf)

Nederlands (NL) (2.54 MB - PDF)

**First published:**

18/01/2021

[View](/nl/documents/product-information/qutavina-epar-product-information_nl.pdf)

norsk (NO) (2.55 MB - PDF)

**First published:**

18/01/2021

[View](/no/documents/product-information/qutavina-epar-product-information_no.pdf)

polski (PL) (2.59 MB - PDF)

**First published:**

18/01/2021

[View](/pl/documents/product-information/qutavina-epar-product-information_pl.pdf)

português (PT) (1.97 MB - PDF)

**First published:**

18/01/2021

[View](/pt/documents/product-information/qutavina-epar-product-information_pt.pdf)

română (RO) (2.07 MB - PDF)

**First published:**

18/01/2021

[View](/ro/documents/product-information/qutavina-epar-product-information_ro.pdf)

slovenčina (SK) (2.55 MB - PDF)

**First published:**

18/01/2021

[View](/sk/documents/product-information/qutavina-epar-product-information_sk.pdf)

slovenščina (SL) (2.54 MB - PDF)

**First published:**

18/01/2021

[View](/sl/documents/product-information/qutavina-epar-product-information_sl.pdf)

Suomi (FI) (2.56 MB - PDF)

**First published:**

18/01/2021

[View](/fi/documents/product-information/qutavina-epar-product-information_fi.pdf)

svenska (SV) (1.98 MB - PDF)

**First published:**

18/01/2021

[View](/sv/documents/product-information/qutavina-epar-product-information_sv.pdf)

24/11/2020

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Qutavina : EPAR - All Authorised presentations

English (EN) (607.61 KB - PDF)

**First published:** 18/01/2021

[View](/en/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-624)

български (BG) (654.59 KB - PDF)

**First published:**

18/01/2021

[View](/bg/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_bg.pdf)

español (ES) (616.53 KB - PDF)

**First published:**

18/01/2021

[View](/es/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_es.pdf)

čeština (CS) (649.54 KB - PDF)

**First published:**

18/01/2021

[View](/cs/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (618.63 KB - PDF)

**First published:**

18/01/2021

[View](/da/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (617.71 KB - PDF)

**First published:**

18/01/2021

[View](/de/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (615.29 KB - PDF)

**First published:**

18/01/2021

[View](/et/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (652.38 KB - PDF)

**First published:**

18/01/2021

[View](/el/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_el.pdf)

français (FR) (616.04 KB - PDF)

**First published:**

18/01/2021

[View](/fr/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (692.56 KB - PDF)

**First published:**

18/01/2021

[View](/hr/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (617.45 KB - PDF)

**First published:**

18/01/2021

[View](/is/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_is.pdf)

italiano (IT) (615.9 KB - PDF)

**First published:**

18/01/2021

[View](/it/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (648.55 KB - PDF)

**First published:**

18/01/2021

[View](/lv/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (633.92 KB - PDF)

**First published:**

18/01/2021

[View](/lt/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (648.08 KB - PDF)

**First published:**

18/01/2021

[View](/hu/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (649.09 KB - PDF)

**First published:**

18/01/2021

[View](/mt/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (616.41 KB - PDF)

**First published:**

18/01/2021

[View](/nl/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (617.27 KB - PDF)

**First published:**

18/01/2021

[View](/no/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_no.pdf)

polski (PL) (653.33 KB - PDF)

**First published:**

18/01/2021

[View](/pl/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_pl.pdf)

português (PT) (617.49 KB - PDF)

**First published:**

18/01/2021

[View](/pt/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_pt.pdf)

română (RO) (630.89 KB - PDF)

**First published:**

18/01/2021

[View](/ro/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (667.48 KB - PDF)

**First published:**

18/01/2021

[View](/sk/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (648.68 KB - PDF)

**First published:**

18/01/2021

[View](/sl/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (615.5 KB - PDF)

**First published:**

18/01/2021

[View](/fi/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (616.39 KB - PDF)

**First published:**

18/01/2021

[View](/sv/documents/all-authorised-presentations/qutavina-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Qutavina Active substance teriparatide International non-proprietary name (INN) or common name teriparatide Therapeutic area (MeSH) Osteoporosis Anatomical therapeutic chemical (ATC) code H05AA02

### Pharmacotherapeutic group

Calcium homeostasis

### Therapeutic indication

Qutavina is indicated in adults.

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.

Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

## Authorisation details

EMA product number EMEA/H/C/005388

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

EuroGenerics Holdings B.V.

Locatellikade 1

Marketing authorisation issued 27/08/2020 Withdrawal of marketing authorisation 24/11/2020

## Assessment history

## Initial marketing authorisation documents

Qutavina : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/379170/2020

English (EN) (3.23 MB - PDF)

**First published:** 18/01/2021

[View](/en/documents/assessment-report/qutavina-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Qutavina

Adopted

Reference Number: EMA/CHMP/341130/2020

English (EN) (132.51 KB - PDF)

**First published:** 26/06/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-qutavina_en.pdf)

#### News on Qutavina

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2020) 26/06/2020

**This page was last updated on** 18/01/2021

## Share this page

[Back to top](#main-content)